Recent Posts
Connect with:
Wednesday / August 10.
HomeminewsTrained Graders Safe, Effective for Stable DED Monitoring

Trained Graders Safe, Effective for Stable DED Monitoring

People with previously treated and stable complications of diabetic eye disease can be safely and cost-effectively monitored by trained graders, freeing ophthalmologists to evaluate and treat people requiring urgent care, according to a UK-wide study led by Queen’s University Belfast.

The new health care surveillance pathway may help ophthalmic units across the world to improve their capacity while saving patients’ sight. It is already having a positive impact on the re-design of NHS services across the UK, having been implemented successfully in several hospitals.

The research, funded by the National Institute for Health Research (NIHR), has been published in leading journals including Ophthalmology, BMJ and NIHR’s Health Technology Assessment.

The EMERALD (the Effectiveness of Multimodal imaging for the Evaluation of Retinal oedemA and new VesseLs in Diabetic retinopathy) diagnostic accuracy study tested a new “ophthalmic grader” pathway. Rather than ophthalmologists, this pathway involves trained graders monitoring people with previously treated and stable complications of diabetic eye disease, namely diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR), based on the reading of images and scans of the back of their eyes.

The grader’s pathway can save £1390 per 100 patients, and the real savings are the ophthalmologist’s time, which can then be redirected to the evaluation of people at high risk of visual loss.

The new health care surveillance pathway may help ophthalmic units across the world to improve their capacity while saving patients’ sight

Professor Noemi Lois, lead researcher and Clinical Professor of Ophthalmology from the Wellcome-Wolfson Institute for Experimental Medicine at Queen’s University Belfast, explained, “Diabetic macular oedema and proliferative diabetic retinopathy, the main sight-threatening complications of diabetic retinopathy can cause blindness if left untreated. It is therefore important to diagnose them and to treat them timely.

“NHS hospitals eye units are under significant pressure given the extremely high number of people that need to be examined and treated and given the insufficient number of ophthalmologists in the UK. Currently, ophthalmologists need to evaluate all patients, even those that are stable after treatment and who are doing well.”

In EMERALD, trained ophthalmic graders were found to achieve satisfactory results when compared to standard care (i.e., ophthalmologists evaluating patients in clinic) while releasing ophthalmologist’s time.

Professor Lois added, “EMERALD showed trained ophthalmic graders are able to determine whether patients with diabetic macular oedema or proliferative diabetic retinopathy, previously successfully treated, remain stable or if on them the disease has reactivated. Thus, they would be able to follow people that have been already treated, releasing ophthalmologists’ time. Ophthalmologists could then use this time to treat timely other patients, for example, those who have indeed diabetic macular oedema or active proliferative diabetic retinopathy and who have not yet received treatment saving their sight.”

Dr Clare Bailey, consultant ophthalmologist at the Bristol Eye Hospital said, “The important data from the EMERALD study has helped us to significantly increase the numbers of people with diabetic retinopathy being seen in ‘imaging/grading’ pathways. This has hugely increased our follow-up capacity, whilst allowing ophthalmologists’ time to be directed to the people with diabetic retinopathy who need treatment or further assessment. This has helped us to deal with the capacity pressures as a result of COVID -19 as well as the longer-term capacity demands due to the increasing prevalence of diabetic retinopathy.”

Dr Caroline Styles, Consultant Ophthalmologist with NHS Fife, added, “Emerald provided us in NHS Fife with the relevant evidence that allowed us to redesign our pathways for people with diabetic eye disease. The involvement of people with diabetes in this study reassures our population that these are safe and appropriate changes, and not just based on cost.”

The EMERALD study was set in 13 National Health Service (NHS) hospitals across the UK and is a large multicentric, UK-wide, National Institute for Health Research (NIHR)-funded diagnostic accuracy study.


By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.